NCT02172885COMPLETEDanonymous

Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta

Sponsor

Source record

Hospital de Cruces

Phase

Source record

PHASE1

Modality

AI-normalized

cell therapy

Target

AI-normalized

Mesenchymal Stem Cells

Indication / condition

AI-normalized

Osteogenesis Imperfecta

Intervention

Source record

Mesenchymal Stem Cells

Related intelligence directories

Indication directory: Osteogenesis Imperfecta Modality directory: cell therapy Target directory: Mesenchymal Stem Cells

Source & freshness

Source record

NCT ID

NCT02172885

Original source

ClinicalTrials.gov

Source last updated

Oct 03, 2023

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02172885

Title

Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta

Sponsor

Hospital de Cruces

Status

COMPLETED

Phase

PHASE1

Condition raw

Osteogenesis Imperfecta

Condition normalized

Osteogenesis Imperfecta

Modality raw

cell therapy

Modality normalized

cell therapy

Target raw

Mesenchymal Stem Cells

Target normalized

Mesenchymal Stem Cells

Interventions

Mesenchymal Stem Cells

Public preview

Source record

The purpose of this study is to determine the safety and effectiveness of five infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI).

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT02172885

Status

COMPLETED

Phase

PHASE1

Sponsor

Hospital de Cruces

Executive brief

Investment-Ready Snapshot

The purpose of this study is to determine the safety and effectiveness of five infusions of characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta (OI).

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedOct 03, 2023

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02172885

Indication

Osteogenesis Imperfecta

Modality

cell therapy

Target

Mesenchymal Stem Cells

Intervention

Mesenchymal Stem Cells

Source record